Trade Mark Journal No.2026/040 2 October 2026

UK00004435505 25 August 2026 (5)

KIVIMAZI

International priority date claimed: 1 June 2026 (United States of America) (99858034)

Class 5: Pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy; Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity.

Regeneron Pharmaceuticals, Inc.

Representative: Appleyard Lees IP LLP